The level of synovial biomarkers following platelet-rich plasma injection for knee osteoarthritis related to radiographic severity

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20220519005

Enrollment

145

Registered

2022-05-19

Start date

2020-07-14

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Although most major guidelines do not include or recommend an intra-articular injection of platelet-rich plasma (PRP), a biologic product prepared from autologous blood, this optional treatment has become a desirable choice of non-surgical treatment for knee OA. Studies regarding PRP applied in knee OA, with various protocols of preparation and injection, showed that it improved patient clinical outcomes by releasing several growth factors and cytokines, promoting reparation and minimization of

Interventions

KL 1 knee OA according to radiographic grading of Kellgren-Lawrence ,KL 2 knee OA according to radiographic grading of Kellgren-Lawrence ,KL 3 knee OA according to radiographic grading of Kellgren-Law

Treatment,Treatment,Treatment,Treatment

KL 1 ,KL 2,KL 3,KL 4

Eligibility

Sex/Gender

All

Age

45 Years to 85 Years

Inclusion criteria

Inclusion criteria: Selection criteria included knee OA according to the American College of Rheumatology (ACR), 45-85 years of age, grade 1 to 4 of radiographic knee OA according to the Kellgren-Lawrence system, body mass index (BMI) < 30, > 90-degree arc of motion, < 10-degree anatomical knee deformity in the coronal plane, and no skin lesion around the affected knee.

Exclusion criteria

Exclusion criteria: Exclusion criteria included inflammatory arthritis, previous knee surgery, knee pain with an antalgic gait, and thrombocytopenia. In addition, all recruited patients had a 2-week washing-out period for any pain killers or non-steroidal anti-inflammatory drugs (NSAIDs) and joint supplements.

Design outcomes

Primary

Measure	Time frame
synovial biomakers at 6 weeks after the intervention level of 12 cytokines from the molecular study	—

Secondary

Measure	Time frame
clinical outcomes within one year after end of the intervention VAS, PROMs (WOMAC and SF-12), and PBMs (TUG, 5*SST, and 3-min WT)	—

Countries

Thailand

Contacts

Public ContactAree Tanavalee

Chulalongkorn University

areetana@hotmail.com0816115086

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026